Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-04-06

Clinical Trial Update: Afrezza Safety and Pharmacokinetics Study in Pediatric Patients [Phase 2]

View source ↗

Summary

A Phase 2 pediatric safety and pharmacokinetics study of Afrezza has completed, with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Afrezza (Technosphere insulin)

Snippet

Sponsor: Mannkind Corporation | Conditions: Type 1 Diabetes Mellitus | Phase 2 | Status: COMPLETED | Results posted: 2021-04-06